Since the ENIGI study has been ongoing since 2010, we have gathered a large database of outcomes after gender-affirming hormone therapy. Here, we will discuss some measures that we are currently collecting or have collected.
The current ENIGI study setup can be divided into ENIGI psychology and ENIGI endocrinology. On this page, information can be found about the study design, methods, data collection and the current outcome variables for the ENIGI endocrinology study.
Study design
The European Network for the Investigation of Gender Incongruence (ENIGI) is a prospective, observational, longitudinal, multicenter study. The first participant was included in Ghent in 2010. Measurements are performed at baseline (start of hormonal treatment), during the first year (three months, six months, nine months, twelve months), after two, three, and five years after starting GAHT.
Inclusion and exclusion criteria
People above the age of 16 (Norway) or 17 (Ghent, Florence, Tel Aviv and Amsterdam), can be included in the study if they ware hormone-naïve at baseline and about to start with hormonal treatment. All participants sign informed consent to be included in the study.
Treatment protocol
All participants in the ENIGI study are treated according to the most up-to-date WPATH treatment guidelines which can be found here.
Data and measures
The most up-to-date ENIGI endocrinology protocol can be found in this paper from 2022 by Cocchetti and colleauges.
Database applications and paper proposals
All researchers applying to use data from the ENIGI endocrinology database are required to complete a paper proposal and send it to the ENIGI PI’s for approval before the data is supplied. Questions about this process can be sent to enigi-studie (at) amsterdamumc.nl .
ENIGI study 